Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics

Viking Therapeutics, Inc. (VKTX): $32.29

3.03 (+10.36%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

VKTX Price/Volume Stats

Current price $32.29 52-week high $99.41
Prev. close $29.26 52-week low $28.64
Day low $28.90 Volume 8,638,420
Day high $34.37 Avg. volume 4,105,569
50-day MA $38.10 Dividend yield N/A
200-day MA $54.94 Market Cap 3.60B

VKTX Stock Price Chart Interactive Chart >


Viking Therapeutics, Inc. (VKTX) Company Bio


Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.


VKTX Latest News Stream


Event/Time News Detail
Loading, please wait...

VKTX Latest Social Stream


Loading social stream, please wait...

View Full VKTX Social Stream

VKTX Price Returns

1-mo N/A
3-mo -37.46%
6-mo -50.04%
1-year -9.65%
3-year 849.71%
5-year 365.95%
YTD -19.76%
2024 116.23%
2023 97.98%
2022 104.35%
2021 -18.29%
2020 -29.80%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!